Asset Details
Do you wish to reserve the book?
Risk prediction of second primary malignant tumor in primary differentiated thyroid cancer patients: a population-based study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Risk prediction of second primary malignant tumor in primary differentiated thyroid cancer patients: a population-based study
Do you wish to request the book?
Risk prediction of second primary malignant tumor in primary differentiated thyroid cancer patients: a population-based study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Risk prediction of second primary malignant tumor in primary differentiated thyroid cancer patients: a population-based study
2023
Overview
Purpose
To investigate the risk factors of second primary malignant tumor (SPMT) in patients with differentiated thyroid cancer (DTC) and establish a competing risk nomogram to predict the probability of SPMT occurrence.
Methods
We retrieved data from the Surveillance, Epidemiology, and End Results (SEER) database for patients diagnosed with DTC between 2000 and 2019. The Fine and Gray subdistribution hazard model was employed to identify SPMT risk factors in the training set and develop a competing risk nomogram. Model evaluation was performed using area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA).
Results
A total of 112,257 eligible patients were included in the study and randomized into a training set (
n
= 112,256) and a validation set (
n
= 33,678). The cumulative incidence rate of SPMT was 15% (
n
= 9528). Age, sex, race, tumor multifocality, and TNM stage were independent risk factors of SPMT. The calibration plots showed good agreement between the predicted and observed SPMT risks. The 10-year AUCs of the calibration plots were 70.2 (68.7–71.6) in the training set and 70.2 (68.7–71.5) in the validation set. Moreover, DCA showed that our proposed model resulted in higher net benefits within a defined range of risk thresholds. The cumulative incidence rate of SPMT differed among risk groups, classified according to nomogram risk scores.
Conclusion
The competing risk nomogram developed in this study exhibits high performance in predicting the occurrence of SPMT in patients with DTC. These findings may help clinicians identify patients at distinct levels of risk of SPMT and develop corresponding clinical management strategies.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
